Barclays
QTTB icon

Barclays’s Q32 Bio QTTB Stock Holding History

Barclays’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$63 – 5525
2025
Q4 		$63 Sell
19
-803
-98% -$2.27K ﹤0.01% 5129
2025
Q3 		$1.63K Sell
822
-231
-22% -$444 ﹤0.01% 5158
2025
Q2 		$1.57K Sell
1,053
-8,117
-89% -$13.8K ﹤0.01% 5049
2025
Q1 		$15.1K Sell
9,170
-3,261
-26% -$8.78K ﹤0.01% 4821
2024
Q4 		$42.8K Buy
12,431
+1,988
+19% +$62.8K ﹤0.01% 4789
2024
Q3 		$466K Buy
10,443
+5,353
+105% +$197K ﹤0.01% 3823
2024
Q2 		$91.4K Buy
5,090
+2,107
+71% +$50.4K ﹤0.01% 3948
2024
Q1 		$50.8K Hold
2,983
– – ﹤0.01% 4611
2023
Q4 		$32.6K Hold
2,983
– – ﹤0.01% 4828
2023
Q3 		$62.8K Hold
2,983
– – ﹤0.01% 3771
2023
Q2 		$47.5K Hold
2,983
– – ﹤0.01% 3856
2023
Q1 		$55.3K Hold
2,983
– – ﹤0.01% 4418
2022
Q4 		$67.7K Hold
2,983
– – ﹤0.01% 4434
2022
Q3 		$86K Hold
2,983
– – ﹤0.01% 3592
2022
Q2 		$106K Sell
2,983
-388
-12% -$13.2K ﹤0.01% 3741
2022
Q1 		$184K Sell
3,371
-2,441
-42% -$152K ﹤0.01% 3474
2021
Q4 		$380K Buy
5,812
+2,977
+105% +$289K ﹤0.01% 3317
2021
Q3 		$402K Buy
2,835
+655
+30% +$83.4K ﹤0.01% 3295
2021
Q2 		$285K Buy
2,180
+471
+28% +$58.8K ﹤0.01% 3384
2021
Q1 		$290K Buy
1,709
+887
+108% +$187K ﹤0.01% 3520
2020
Q4 		$167K Sell
822
-212
-21% -$41K ﹤0.01% 3870
2020
Q3 		$199K Sell
1,034
-152
-13% -$34.1K ﹤0.01% 3851
2020
Q2 		$324K Buy
1,186
+706
+147% +$188K ﹤0.01% 3680
2020
Q1 		$134K Sell
480
-996
-67% -$305K ﹤0.01% 4579
2019
Q4 		$550K Buy
1,476
+634
+75% +$182K ﹤0.01% 4221
2019
Q3 		$274K Sell
842
-29
-3% -$9.86K ﹤0.01% 4734
2019
Q2 		$307K Buy
871
+465
+115% +$183K ﹤0.01% 4747
2019
Q1 		$202K Buy
406
+45
+12% +$20.1K ﹤0.01% 4817
2018
Q4 		$145K Buy
361
+144
+66% +$54.5K ﹤0.01% 4797
2018
Q3 		$89K Buy
217
+107
+97% +$36.3K ﹤0.01% 5660
2018
Q2 		$41K Buy
+110
New +$39.4K ﹤0.01% 5762

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's QTTB Position: Q1 2026 in Review

Barclays sold out of Q32 Bio (QTTB) in Q1 2026, closing a stake of 19 shares — an estimated $63 sold.

Barclays first reported a position in QTTB in Q2 2018 and held it in 31 quarters. The position peaked at $550K in Q4 2019. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Barclays reported no remaining Q32 Bio position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 19 Q32 Bio shares in Q1 2026, an estimated $63.
  • Barclays first reported a position in Q32 Bio in Q2 2018 and held it in 31 quarters.
  • Barclays's Q32 Bio position peaked at $550K in Q4 2019.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.